Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 29.

Article

Jove, M, Spencer, J, Clench, M et al. (2 more authors) (2019) Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. Critical Reviews in Oncology/Hematology. ISSN 1040-8428

Kirschbrown, WP, Kagedal, M, Wang, B et al. (15 more authors) (2019) Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology, 83 (6). pp. 1147-1158. ISSN 0344-5704

Tripathy, D, Tolaney, SM, Seidman, AD et al. (9 more authors) (2019) ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncology. ISSN 1479-6694

Twelves, C, Anthoney, A, Savulsky, CI et al. (9 more authors) (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120 (6). pp. 579-586. ISSN 0007-0920

Rugo, HS, Cortes, J, Awada, A et al. (12 more authors) (2018) Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 24 (14). pp. 3348-3357. ISSN 1078-0432

Perkins, EJ, Posada, M, Kellie Turner, P et al. (3 more authors) (2018) Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam. European Journal of Drug Metabolism and Pharmacokinetics, 43 (3). pp. 355-367. ISSN 0378-7966

Blackwell, K, Gligorov, J, Jacobs, I et al. (1 more author) (2018) The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. Clinical Breast Cancer, 18 (2). pp. 95-113. ISSN 1526-8209

Başaran, GA, Twelves, C, Diéras, V et al. (2 more authors) (2018) Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 63. pp. 144-155. ISSN 0305-7372

Cortés, J, Rugo, HS, Awada, A et al. (16 more authors) (2017) Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (vol 165, pg 329, 2017). Breast Cancer Research and Treatment, 166 (1). pp. 327-328. ISSN 0167-6806

Cortés, J, Rugo, HS, Awada, A et al. (16 more authors) (2017) Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment, 165 (2). pp. 329-341. ISSN 0167-6806

Baker, K, Dunwoodie, E, Jones, RG et al. (8 more authors) (2017) Process Mining Routinely Collected Electronic Health Records to Define Real-Life Clinical Pathways during Chemotherapy. International Journal of Medical Informatics, 103. pp. 32-41. ISSN 1386-5056

Twelves, C, Cortés, J, Shaughnessy, JO et al. (16 more authors) (2017) Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician’s choice: Results from the randomised phase III BEACON trial. European Journal of Cancer, 76. pp. 205-215. ISSN 0959-8049

Cortés, J, Rugo, HS, Twelves, C et al. (10 more authors) (2016) Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. SpringerPlus, 5 (1). 1033. ISSN 2193-1801

Dorling, L, Kar, S, Michailidou, K et al. (12 more authors) (2016) The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity: A case-control study. PLoS ONE, 11 (7). ISSN 1932-6203

Twelves, C, Awada, A, Cortes, J et al. (6 more authors) (2016) Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer: Basic and Clinical Research, 10. pp. 77-84.

Hawsawi, Y, Humphries, MP orcid.org/0000-0003-1306-7012, Wright, A et al. (8 more authors) (2016) Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro. Oncotarget, 7 (22). pp. 32129-32143. ISSN 1949-2553

Twelves, C, Jove, M, Gombos, A et al. (1 more author) (2016) Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer. Critical Reviews in Oncology/Hematology, 100. pp. 74-87. ISSN 1040-8428

Cortes, J, Hudgens, S, Twelves, C et al. (7 more authors) (2015) Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast cancer research and treatment, 154 (3). 509 - 520. ISSN 0167-6806

Kaufman, PA, Awada, A, Twelves, C et al. (7 more authors) (2015) Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 33 (6). pp. 594-601. ISSN 0732-183X

Chu, E, Haller, D, Cartwright, T et al. (7 more authors) (2014) Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. British Journal of Cancer, 110 (6). pp. 1438-1445. ISSN 0007-0920

Downing, A, Twelves, C, Forman, D et al. (2 more authors) (2014) Time to begin adjuvant chemotherapy and survival in breast cancer patients: a retrospective observational study using latent class analysis. Breast Journal, 20 (1). 29 - 36. ISSN 1075-122X

Hawsawi, Y, El-Gendy, R, Twelves, C et al. (2 more authors) (2013) Insulin-like growth factor - Oestradiol crosstalk and mammary gland tumourigenesis. BBA - Reviews on Cancer, 1836 (2). 345 - 353. ISSN 0304-419X

Kaufmann, PA, Cortes, J, Awada, A et al. (8 more authors) (2013) A Phase Ill, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses. Onkologie: international journal for cancer research and treatment, 36 (Suppl 7). p. 97. ISSN 0378-584X

Proceedings Paper

Cheeseman, S, Thompson, M, Riaz, M et al. (9 more authors) (2018) Characteristics and treatment patterns in patients with locally advanced and metastatic hormone receptor positive (HR+ ), human epidermal growth factor 2 negative (HER2-) breast cancer in clinical practice: retrospective analysis from Leeds Cancer Centre. In: Value in Health. ISPOR Europe 2018, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S51-S51.

Jove Casulleras, M, Spencer, J, Loadman, P et al. (7 more authors) (2018) Abstract 4926: Preclinical intratumoral pharmacokinetics (PK) of capecitabine (Cap) given +/- eribulin (Eri). In: Cancer Research. AACR Annual Meeting 2018, 14-18 Apr 2018, Chicago, IL, USA. American Association for Cancer Research .

Ferrari, L, Gerratana, L, Jove, M et al. (4 more authors) (2016) Clinical decision making in patients with metastatic breast cancer in the United Kingdom (UK) and Italy. In: Annals of Oncology. 41st ESMO Congress (ESMO 2016), 07-11 Oct 2016, Copenhagen, Denmark. Oxford University Press .

Ferrari, L, Gerratana, L, Jove, M et al. (16 more authors) (2016) Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy. In: Annals of Oncology. XVIII National Congress of Medical Oncology, 28-30 Oct 2016, Rome, Italy. Oxford University Press , iv63-iv63.

O'Shaughnessy, J, Rugo, H, Awada, A et al. (16 more authors) (2016) Etirinotecan pegol (EP) significantly improves overall survival in patients with advanced breast cancer (aBC) and a history of brain metastases (BM). In: European Journal of Cancer. 10th European Breast Cancer Conference (EBCC-10), 09-11 Mar 2016, Amsterdam, Netherlands. Elsevier , S111-S112.

Hawsawi, YM, Jove, M, Humphries, M et al. (5 more authors) (2015) Role of Insulin like Growth Factor Binding Proteins and Tamoxifen Resistance in Breast Cancer Epithelial Cells. In: Journal of Pathology. Dublin Pathology 2015. 8th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 23-25 Jun 2015, Dublin, Ireland. Wiley , S19-S19.

This list was generated on Sun Aug 11 13:28:02 2019 BST.